Lantern Pharma Inc. (NASDAQ: LTRN) announced it will host an investor, analyst, and shareholder briefing on April 9, 2026, at 8:30 a.m. Eastern Time. The webcast will feature a live demonstration of withZeta.ai, described as the first multi-agentic AI co-scientist platform designed for rare cancer drug discovery, development, and clinical trial design. CEO Panna Sharma and Chief Scientific Officer Kishor Bhatia will participate in the event, which aims to showcase the platform's capabilities, commercial architecture, competitive positioning, and revenue strategy.
The briefing will also provide an overview of the rare cancer market opportunity and Lantern Pharma's growth roadmap. The company positions withZeta.ai as a transformative tool in oncology, leveraging artificial intelligence to address complex challenges in drug development. This demonstration represents a significant step in communicating the platform's value proposition to the investment community and stakeholders interested in the convergence of biotechnology and advanced computational science.
Lantern Pharma is an AI-driven company focused on transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning platform, RADR®, utilizes over 200 billion oncology-focused data points and a library of more than 200 advanced machine learning algorithms. The company states this infrastructure helps solve real-world problems in oncology drug development and generates oncology medicines at dramatically reduced costs and accelerated timelines.
According to the company, its AI-driven approach has accelerated the development of a growing pipeline of drug candidates spanning multiple cancer indications, including both solid tumors and blood cancers, as well as an antibody-drug conjugate program. Lantern Pharma reports that, on average, its newly developed drug programs advance from initial AI insights to first-in-human clinical trials in two to three years at an approximate cost of $1.0 to $2.5 million per program. This contrasts sharply with traditional drug development, which often takes over a decade and costs billions of dollars.
The company's lead development programs include a Phase 2 clinical program and multiple planned Phase 1b/2a clinical trials. Lantern Pharma has also established a wholly-owned subsidiary, Starlight Therapeutics, to focus exclusively on the clinical execution of therapies for central nervous system and brain cancers. The company estimates its AI-driven pipeline of innovative product candidates has a combined annual market potential exceeding $15 billion.
The upcoming investor briefing underscores the growing importance of artificial intelligence in the pharmaceutical and biotechnology sectors, particularly in oncology. The demonstration of withZeta.ai could influence how investors and analysts perceive the company's technological edge and long-term commercial potential. For the industry, platforms like withZeta.ai represent a paradigm shift, potentially enabling more efficient targeting of rare cancers, which often have limited treatment options and high unmet medical needs. The ability to reduce development timelines and costs could make drug discovery for these conditions more viable, potentially bringing new therapies to patients faster. The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN.
